Unadjusted and adjusted associations of per 1 SD increase in time in target range for systolic blood pressure and cardiovascular outcomes
| TTR . | Events (no.) . | Follow-up duration (person-year) . | Incident rate (per 1000 person-years) . | Unadjusted HR* (95% CI) . | Model 1 HR* (95% CI) . | Model 2 HR* (95% CI) . | Model 3 HR* (95% CI) . |
|---|---|---|---|---|---|---|---|
| Primary outcome | 423 | 9316 | 45.41 (41.28–49.95) | 0.723 (0.654–0.800) | 0.767 (0.690–0.852) | 0.770 (0.692–0.857) | 0.746 (0.666–0.834) |
| Secondary outcome 1 | 264 | 10 228 | 25.81 (22.88–29.12) | 0.721 (0.634–0.819) | 0.738 (0.645–0.844) | 0.742 (0.647–0.849) | 0.735 (0.636–0.848) |
| Secondary outcome 2 | 416 | 9316 | 44.65 (40.56–49.16) | 0.730 (0.660–0.808) | 0.774 (0.696–0.861) | 0.778 (0.699–0.866) | 0.755 (0.674–0.846) |
| Secondary outcome 3 | 692 | 9316 | 74.28 (68.95–80.03) | 0.827 (0.766–0.894) | 0.873 (0.805–0.947) | 0.869 (0.801–0.944) | 0.845 (0.775–0.922) |
| TTR . | Events (no.) . | Follow-up duration (person-year) . | Incident rate (per 1000 person-years) . | Unadjusted HR* (95% CI) . | Model 1 HR* (95% CI) . | Model 2 HR* (95% CI) . | Model 3 HR* (95% CI) . |
|---|---|---|---|---|---|---|---|
| Primary outcome | 423 | 9316 | 45.41 (41.28–49.95) | 0.723 (0.654–0.800) | 0.767 (0.690–0.852) | 0.770 (0.692–0.857) | 0.746 (0.666–0.834) |
| Secondary outcome 1 | 264 | 10 228 | 25.81 (22.88–29.12) | 0.721 (0.634–0.819) | 0.738 (0.645–0.844) | 0.742 (0.647–0.849) | 0.735 (0.636–0.848) |
| Secondary outcome 2 | 416 | 9316 | 44.65 (40.56–49.16) | 0.730 (0.660–0.808) | 0.774 (0.696–0.861) | 0.778 (0.699–0.866) | 0.755 (0.674–0.846) |
| Secondary outcome 3 | 692 | 9316 | 74.28 (68.95–80.03) | 0.827 (0.766–0.894) | 0.873 (0.805–0.947) | 0.869 (0.801–0.944) | 0.845 (0.775–0.922) |
*HR per 1-SD increase in time in target range.
TTR, time in target range; SD, standard deviation; HR, hazard ratio; CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; CVD, cardiovascular disease. Primary outcome: stroke, myocardial infarction, angina pectoris, or cardiac death; secondary outcome 1: stroke, myocardial infarction, or cardiac death; secondary outcome 2: stroke, myocardial infarction, or angina pectoris; secondary outcome 3: stroke, myocardial infarction, angina pectoris, or all-cause mortality.
Model 1: Adjusted for baseline demographics (age and sex), smoking status, BMI, SBP, TG, LDL-C, eGFR, use of antihypertensive medication, diabetes mellitus, and CVD status.
Model 2: Adjusted for baseline demographics (age and sex), smoking status, BMI, SBP, TG, LDL-C, eGFR, use of antihypertensive medication, diabetes mellitus, CVD status, and last SBP.
Model 3: Adjusted for baseline demographics (age and sex), smoking status, BMI, SBP, TG, LDL-C, eGFR, use of antihypertensive medication, diabetes mellitus, CVD status, and mean SBP.
Unadjusted and adjusted associations of per 1 SD increase in time in target range for systolic blood pressure and cardiovascular outcomes
| TTR . | Events (no.) . | Follow-up duration (person-year) . | Incident rate (per 1000 person-years) . | Unadjusted HR* (95% CI) . | Model 1 HR* (95% CI) . | Model 2 HR* (95% CI) . | Model 3 HR* (95% CI) . |
|---|---|---|---|---|---|---|---|
| Primary outcome | 423 | 9316 | 45.41 (41.28–49.95) | 0.723 (0.654–0.800) | 0.767 (0.690–0.852) | 0.770 (0.692–0.857) | 0.746 (0.666–0.834) |
| Secondary outcome 1 | 264 | 10 228 | 25.81 (22.88–29.12) | 0.721 (0.634–0.819) | 0.738 (0.645–0.844) | 0.742 (0.647–0.849) | 0.735 (0.636–0.848) |
| Secondary outcome 2 | 416 | 9316 | 44.65 (40.56–49.16) | 0.730 (0.660–0.808) | 0.774 (0.696–0.861) | 0.778 (0.699–0.866) | 0.755 (0.674–0.846) |
| Secondary outcome 3 | 692 | 9316 | 74.28 (68.95–80.03) | 0.827 (0.766–0.894) | 0.873 (0.805–0.947) | 0.869 (0.801–0.944) | 0.845 (0.775–0.922) |
| TTR . | Events (no.) . | Follow-up duration (person-year) . | Incident rate (per 1000 person-years) . | Unadjusted HR* (95% CI) . | Model 1 HR* (95% CI) . | Model 2 HR* (95% CI) . | Model 3 HR* (95% CI) . |
|---|---|---|---|---|---|---|---|
| Primary outcome | 423 | 9316 | 45.41 (41.28–49.95) | 0.723 (0.654–0.800) | 0.767 (0.690–0.852) | 0.770 (0.692–0.857) | 0.746 (0.666–0.834) |
| Secondary outcome 1 | 264 | 10 228 | 25.81 (22.88–29.12) | 0.721 (0.634–0.819) | 0.738 (0.645–0.844) | 0.742 (0.647–0.849) | 0.735 (0.636–0.848) |
| Secondary outcome 2 | 416 | 9316 | 44.65 (40.56–49.16) | 0.730 (0.660–0.808) | 0.774 (0.696–0.861) | 0.778 (0.699–0.866) | 0.755 (0.674–0.846) |
| Secondary outcome 3 | 692 | 9316 | 74.28 (68.95–80.03) | 0.827 (0.766–0.894) | 0.873 (0.805–0.947) | 0.869 (0.801–0.944) | 0.845 (0.775–0.922) |
*HR per 1-SD increase in time in target range.
TTR, time in target range; SD, standard deviation; HR, hazard ratio; CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; CVD, cardiovascular disease. Primary outcome: stroke, myocardial infarction, angina pectoris, or cardiac death; secondary outcome 1: stroke, myocardial infarction, or cardiac death; secondary outcome 2: stroke, myocardial infarction, or angina pectoris; secondary outcome 3: stroke, myocardial infarction, angina pectoris, or all-cause mortality.
Model 1: Adjusted for baseline demographics (age and sex), smoking status, BMI, SBP, TG, LDL-C, eGFR, use of antihypertensive medication, diabetes mellitus, and CVD status.
Model 2: Adjusted for baseline demographics (age and sex), smoking status, BMI, SBP, TG, LDL-C, eGFR, use of antihypertensive medication, diabetes mellitus, CVD status, and last SBP.
Model 3: Adjusted for baseline demographics (age and sex), smoking status, BMI, SBP, TG, LDL-C, eGFR, use of antihypertensive medication, diabetes mellitus, CVD status, and mean SBP.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
